Download PDF
Semin intervent Radiol 2024; 41(02): 121-128
DOI: 10.1055/s-0044-1786725
Review Article

An Interventional Radiologist's Guide to Lung Cancer

Adam G. Fish
1   Section of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut
,
David C. Madoff
1   Section of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut
2   Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
3   Section of Surgical Oncology, Department of Surgery, Yale School of Medicine, New Haven, Connecticut
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Lung cancer continues to be the third leading cause of cancer and the leading cause of cancer deaths. As the field of interventional oncology continues to grow, interventional radiologists are increasingly treating lung cancer patients. Involvement begins with tissue diagnosis for which biomarkers and immunohistochemistry are used to guide selective and advanced medical therapies. An interventional radiologist must be aware of the rationale behind tissue diagnosis and techniques to minimize biopsy complications. Staging is an important part of tumor board conversations and drives treatment pathways. Surgical therapy remains the gold standard for early-stage disease but with an aging population the need for less invasive treatments such as radiation therapy and ablation continue to grow. The interventionalist must be aware of the indications, techniques, and pre- and posttherapy managements for percutaneous ablation. Endovascular therapy is broadly divided into therapeutic treatment of lung cancer, which is gaining traction, and treatment of lung cancer complications such as hemoptysis. This review aims to provide a good basis for interventional radiologists treating lung cancer patients.

Keywords

lung cancer - percutaneous ablation - bronchial artery embolization - pulmonary - artery pseudoaneurysms - lung cancer hemoptysis - interventional radiology


Publication History

Article published online:
10 July 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet 2021; 398 (10299): 535-554
    CrossrefPubMedSearch in Google Scholar
  • 2 Howlader N, Forjaz G, Mooradian MJ. et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med 2020; 383 (07) 640-649
    CrossrefPubMedSearch in Google Scholar
  • 3 Miller KD, Nogueira L, Devasia T. et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022; 72 (05) 409-436
    CrossrefPubMedSearch in Google Scholar
  • 4 Aberle DR, Adams AM, Berg CD. et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (05) 395-409
    CrossrefPubMedSearch in Google Scholar
  • 5 Postmus PE, Kerr KM, Oudkerk M. et al; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 04) iv1-iv21
    CrossrefPubMedSearch in Google Scholar
  • 6 Mouli SK, Kurilova I, Sofocleous CT, Lewandowski RJ. The role of percutaneous image-guided thermal ablation for the treatment of pulmonary malignancies. AJR Am J Roentgenol 2017; 209 (04) 740-751
    CrossrefPubMedSearch in Google Scholar
  • 7 Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization Classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 2015; 10 (09) 1240-1242
    CrossrefPubMedSearch in Google Scholar
  • 8 Singal G, Miller PG, Agarwala V. et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA 2019; 321 (14) 1391-1399
    CrossrefPubMedSearch in Google Scholar
  • 9 Bensch F, van der Veen EL, Lub-de Hooge MN. et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 2018; 24 (12) 1852-1858
    CrossrefPubMedSearch in Google Scholar
  • 10 Kalemkerian GP, Narula N, Kennedy EB. et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 2018; 36 (09) 911-919
    CrossrefPubMedSearch in Google Scholar
  • 11 Lynch TJ, Bell DW, Sordella R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 (21) 2129-2139
    CrossrefPubMedSearch in Google Scholar
  • 12 Zugazagoitia J, Ramos I, Trigo JM. et al. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol 2019; 30 (02) 290-296
    CrossrefPubMedSearch in Google Scholar
  • 13 Wu Y, Li P, Zhang H. et al. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cancer 2013; 132 (02) E37-E47
    CrossrefPubMedSearch in Google Scholar
  • 14 Goldstraw P, Chansky K, Crowley J. et al; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11 (01) 39-51
    CrossrefPubMedSearch in Google Scholar
  • 15 Schneider F, Smith MA, Lane MC, Pantanowitz L, Dacic S, Ohori NP. Adequacy of core needle biopsy specimens and fine-needle aspirates for molecular testing of lung adenocarcinomas. Am J Clin Pathol 2015; 143 (02) 193-200 , quiz 306
    CrossrefPubMedSearch in Google Scholar
  • 16 Deng CJ, Dai FQ, Qian K. et al. Clinical updates of approaches for biopsy of pulmonary lesions based on systematic review. BMC Pulm Med 2018; 18 (01) 146
    CrossrefPubMedSearch in Google Scholar
  • 17 Chung C, Kim Y, Park D. Transthoracic needle biopsy: how to maximize diagnostic accuracy and minimize complications. Tuberc Respir Dis (Seoul) 2020; 83 (Suppl. 01) S17-S24
    CrossrefPubMedSearch in Google Scholar
  • 18 Kim GR, Hur J, Lee SM. et al. CT fluoroscopy-guided lung biopsy versus conventional CT-guided lung biopsy: a prospective controlled study to assess radiation doses and diagnostic performance. Eur Radiol 2011; 21 (02) 232-239
    CrossrefPubMedSearch in Google Scholar
  • 19 Lee MH, Lubner MG, Hinshaw JL, Pickhardt PJ. Ultrasound guidance versus CT guidance for peripheral lung biopsy: performance according to lesion size and pleural contact. AJR Am J Roentgenol 2018; 210 (03) W110-W117
    CrossrefPubMedSearch in Google Scholar
  • 20 Najafi A, Al Ahmar M, Bonnet B. et al. The PEARL approach for CT-guided lung biopsy: assessment of complication rate. Radiology 2022; 302 (02) 473-480
    CrossrefPubMedSearch in Google Scholar
  • 21 Lim E, Harris RA, McKeon HE. et al. Impact of video-assisted thoracoscopic lobectomy versus open lobectomy for lung cancer on recovery assessed using self-reported physical function: VIOLET RCT. Health Technol Assess 2022; 26 (48) 1-162
    CrossrefPubMedSearch in Google Scholar
  • 22 Palussière J, Cazayus M, Cousin S. et al. Is there a role for percutaneous ablation for early stage lung cancer? What is the evidence?. Curr Oncol Rep 2021; 23 (07) 81
    CrossrefPubMedSearch in Google Scholar
  • 23 Ball D, Mai GT, Vinod S. et al; TROG 09.02 CHISEL Investigators. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2019; 20 (04) 494-503
    CrossrefPubMedSearch in Google Scholar
  • 24 Ettinger DS, Wood DE, Aisner DL. et al. Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20 (05) 497-530
    CrossrefPubMedSearch in Google Scholar
  • 25 Nezami N, Khorshidi F, Mansur A, Habibollahi P, Camacho JC. Primary and metastatic lung cancer: rationale, indications, and outcomes of thermal ablation. Clin Lung Cancer 2023; 24 (05) 389-400
    CrossrefPubMedSearch in Google Scholar
  • 26 Genshaft SJ, Suh RD, Abtin F. et al. Society of Interventional Radiology Multidisciplinary Position Statement on percutaneous ablation of non-small cell lung cancer and metastatic disease to the lungs: endorsed by the Canadian Association for Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology. J Vasc Interv Radiol 2021; 32 (08) 1241.e1-1241.e12
    CrossrefPubMedSearch in Google Scholar
  • 27 Venturini M, Cariati M, Marra P, Masala S, Pereira PL, Carrafiello G. CIRSE Standards of Practice on thermal ablation of primary and secondary lung tumours. Cardiovasc Intervent Radiol 2020; 43 (05) 667-683
    CrossrefPubMedSearch in Google Scholar
  • 28 Prud'homme C, Deschamps F, Moulin B. et al. Image-guided lung metastasis ablation: a literature review. Int J Hyperthermia 2019; 36 (02) 37-45
    CrossrefPubMedSearch in Google Scholar
  • 29 Patel IJ, Rahim S, Davidson JC. et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol 2019; 30 (08) 1168-1184.e1
    CrossrefPubMedSearch in Google Scholar
  • 30 Iguchi T, Hiraki T, Gobara H. et al. Percutaneous radiofrequency ablation of lung tumors close to the heart or aorta: evaluation of safety and effectiveness. J Vasc Interv Radiol 2007; 18 (06) 733-740
    CrossrefPubMedSearch in Google Scholar
  • 31 Hong K, Georgiades C. Radiofrequency ablation: mechanism of action and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl): S179-S186
    CrossrefPubMedSearch in Google Scholar
  • 32 Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee Jr FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005; 236 (01) 132-139
    CrossrefPubMedSearch in Google Scholar
  • 33 Tafti BA, Genshaft S, Suh R, Abtin F. Lung ablation: indications and techniques. Semin Intervent Radiol 2019; 36 (03) 163-175
    Thieme ConnectPubMedSearch in Google Scholar
  • 34 Lubner MG, Brace CL, Hinshaw JL, Lee Jr FT. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl): S192-S203
    CrossrefPubMedSearch in Google Scholar
  • 35 Sun Y, Wang Y, Ni X. et al. Comparison of ablation zone between 915- and 2,450-MHz cooled-shaft microwave antenna: results in in vivo porcine livers. AJR Am J Roentgenol 2009; 192 (02) 511-514
    CrossrefPubMedSearch in Google Scholar
  • 36 Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences?. Curr Probl Diagn Radiol 2009; 38 (03) 135-143
    CrossrefPubMedSearch in Google Scholar
  • 37 Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology 1998; 37 (03) 171-186
    CrossrefPubMedSearch in Google Scholar
  • 38 Cooper IS. Cryobiology as viewed by the surgeon. Cryobiology 1964; 51: 44-51
    CrossrefPubMedSearch in Google Scholar
  • 39 de Baère T, Aupérin A, Deschamps F. et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 2015; 26 (05) 987-991
    CrossrefPubMedSearch in Google Scholar
  • 40 Mansur A, Garg T, Shrigiriwar A. et al. Image-guided percutaneous ablation for primary and metastatic tumors. Diagnostics (Basel) 2022; 12 (06) 12
    PubMedSearch in Google Scholar
  • 41 Páez-Carpio A, Gómez FM, Isus Olivé G. et al. Image-guided percutaneous ablation for the treatment of lung malignancies: current state of the art. Insights Imaging 2021; 12 (01) 57
    CrossrefPubMedSearch in Google Scholar
  • 42 Li G, Xue M, Chen W, Yi S. Efficacy and safety of radiofrequency ablation for lung cancers: A systematic review and meta-analysis. Eur J Radiol 2018; 100: 92-98
    CrossrefPubMedSearch in Google Scholar
  • 43 Zhao Q, Wang J, Fu YL, Hu B. Radiofrequency ablation for stage <IIB non-small cell lung cancer: opportunities, challenges, and the road ahead. Thorac Cancer 2023; 14 (32) 3181-3190
    CrossrefPubMedSearch in Google Scholar
  • 44 Grieco CA, Simon CJ, Mayo-Smith WW, DiPetrillo TA, Ready NE, Dupuy DE. Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer. J Vasc Interv Radiol 2006; 17 (07) 1117-1124
    CrossrefPubMedSearch in Google Scholar
  • 45 Timmerman RD, Hu C, Michalski JM. et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer. JAMA Oncol 2018; 4 (09) 1287-1288
    CrossrefPubMedSearch in Google Scholar
  • 46 Laeseke P, Ng C, Ferko N. et al. Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: a systematic literature review and meta-analysis. Lung Cancer 2023; 182: 107259
    CrossrefPubMedSearch in Google Scholar
  • 47 Macchi M, Belfiore MP, Floridi C. et al. Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial. Med Oncol 2017; 34 (05) 96
    CrossrefPubMedSearch in Google Scholar
  • 48 Ni Y, Ye X, Yang X. et al. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment. J Cancer Res Clin Oncol 2020; 146 (01) 197-203
    CrossrefPubMedSearch in Google Scholar
  • 49 Moore W, Talati R, Bhattacharji P, Bilfinger T. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. J Vasc Interv Radiol 2015; 26 (03) 312-319
    CrossrefPubMedSearch in Google Scholar
  • 50 Xu Z, Wang X, Ke H, Lyu G. Cryoablation is superior to radiofrequency ablation for the treatment of non-small cell lung cancer: a meta-analysis. Cryobiology 2023; 112: 104560
    CrossrefPubMedSearch in Google Scholar
  • 51 Mabud TS, Swilling D, Guichet P. et al. Pulmonary cryoablation outcomes in octogenarians and nonagenarians with primary lung cancer. J Vasc Interv Radiol 2023; 34 (11) 2006-2011
    CrossrefPubMedSearch in Google Scholar
  • 52 Tian Y, Qi X, Jiang X, Shang L, Xu K, Shao H. Cryoablation and immune synergistic effect for lung cancer: a review. Front Immunol 2022; 13: 950921
    CrossrefPubMedSearch in Google Scholar
  • 53 Feng J, Guiyu D, Xiongwen W. The clinical efficacy of argon-helium knife cryoablation combined with nivolumab in the treatment of advanced non-small cell lung cancer. Cryobiology 2021; 102: 92-96
    CrossrefPubMedSearch in Google Scholar
  • 54 Yuan Z, Wang Y, Zhang J, Zheng J, Li W. A meta-analysis of clinical outcomes after radiofrequency ablation and microwave ablation for lung cancer and pulmonary metastases. J Am Coll Radiol 2019; 16 (03) 302-314
    CrossrefPubMedSearch in Google Scholar
  • 55 Kashima M, Yamakado K, Takaki H. et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center's experiences. AJR Am J Roentgenol 2011; 197 (04) W576-80
    CrossrefPubMedSearch in Google Scholar
  • 56 Jiang B, Mcclure MA, Chen T, Chen S. Efficacy and safety of thermal ablation of lung malignancies: a network meta-analysis. Ann Thorac Med 2018; 13 (04) 243-250
    CrossrefPubMedSearch in Google Scholar
  • 57 Hori S, Nakamura T, Kennoki N, Dejima I, Hori A. Transarterial management of advance lung cancer. Jpn J Clin Oncol 2021; 51 (06) 851-856
    CrossrefPubMedSearch in Google Scholar
  • 58 Walter FM, Rubin G, Bankhead C. et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. Br J Cancer 2015; 112 (Suppl. 01) S6-S13
    CrossrefPubMedSearch in Google Scholar
  • 59 Syha R, Benz T, Hetzel J. et al. Bronchial artery embolization in hemoptysis: 10-year survival and recurrence-free survival in benign and malignant etiologies - a retrospective study. Röfo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 2016; 188 (11) 1061-1066
    Thieme ConnectPubMedSearch in Google Scholar
  • 60 Le Tat T, Carlier R, Zhang N. et al. Endovascular management of life-threatening hemoptysis in primary lung cancer: a retrospective study. Cardiovasc Intervent Radiol 2023; 46 (07) 891-900
    CrossrefPubMedSearch in Google Scholar